Prevention of Syncope (fainting) Trial 11


About 20% of adults faint regularly. No treatments are proven useful in executed clinical trials. This is a study to test the theory that Ondansetron reduces the time to a recurrence of faint in a TILT test. In this study half the patients will receive Ondansetron the night before and the morning of the study day ( TILT Table test) the other half will receive a Placebo. you need to fill in two surveys. No follow-up needed after the study day.


Currently recruiting participants: Yes

Eligible gender: Male, Female, Transgender, Other

Eligible ages: 18 to 99

Inclusion criteria:

1. ≥1 faints in the year preceding enrolment
2. Vasovagal Syncope
3. Age ≥ 18 years

Exclusion criteria:

(1) other causes of syncope, such as ventricular tachycardia, complete heart block, orthostatic hypotension or hypersensitive carotid sinus syndrome
(2) an inability to give informed consent
(3) important valvular, coronary, myocardial or conduction abnormality or significant arrhythmia
(4) hypertrophic cardiomyopathy
(5) a permanent pacemaker
(6) a seizure disorder
(7) hypertension defined as >160/90 mm Hg
(8) pregnancy
(9) lactating women
(10) glaucoma
(11) medications with known effects on BP
(12) Known hypersensitivity to ondansetron and related medications
(13) other factors which, in the investigator’s opinion, would prevent the subject from completing the protocol.


Fill out the following form if you want to participate in this research

Method of contact

Additional information

Contact information

Rasha Hamzeh Email: Phone number:403-220-8897

Principal investigator:

Robert Stanley Sheldon

Clinical trial: